Establishment Labs (ESTA) Stock Price, News & Analysis

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Establishment Labs in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ESTA shares.
View ESTA analyst ratings or view top-rated stocks.

5 equities research analysts have issued 12-month price targets for Establishment Labs' stock. Their ESTA share price targets range from $47.00 to $65.00. On average, they expect the company's stock price to reach $55.00 in the next year. This suggests a possible upside of 4.6% from the stock's current price.
View analysts price targets for ESTA or view top-rated stocks among Wall Street analysts.

Establishment Labs' stock was trading at $25.89 at the start of the year. Since then, ESTA shares have increased by 103.1% and is now trading at $52.57.
View the best growth stocks for 2024 here.

Establishment Labs saw a increase in short interest in March. As of March 31st, there was short interest totaling 4,930,000 shares, an increase of 8.1% from the March 15th total of 4,560,000 shares. Based on an average trading volume of 457,400 shares, the short-interest ratio is currently 10.8 days. Currently, 21.7% of the company's stock are short sold.
View Establishment Labs' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ESTA earnings forecast.

Establishment Labs Holdings Inc. (NASDAQ:ESTA) posted its earnings results on Wednesday, February, 28th. The company reported ($0.79) EPS for the quarter, beating analysts' consensus estimates of ($0.95) by $0.16. The firm had revenue of $31.60 million for the quarter, compared to the consensus estimate of $31.44 million. Establishment Labs had a negative trailing twelve-month return on equity of 357.81% and a negative net margin of 47.53%. Establishment Labs's quarterly revenue was down 27.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.55) earnings per share.

ETFs with the largest weight of Establishment Labs (NASDAQ:ESTA) stock in their portfolio include Simplify Health Care ETF (PINK).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

Establishment Labs issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $174.0 million-$184.0 million, compared to the consensus revenue estimate of $173.7 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Establishment Labs investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Sientra (SIEN), Allergan (AGN), BCE (BCE), Canadian Imperial Bank of Commerce (CM), Canadian Natural Resources (CNQ), Chevron (CVX) and Evolus (EOLS).

Establishment Labs (ESTA) raised $50 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 3,100,000 shares at $15.00-$17.00 per share. Jefferies and Cowen served as the underwriters for the IPO and BTIG was co-manager.

Establishment Labs' stock is owned by a number of institutional and retail investors. Top institutional investors include Stableford Capital II LLC (0.11%). Insiders that own company stock include Dennis E Condon, Dennis E Condon, Edward J Schutter, Jw Asset Management, Llc, Leslie Gillin, Lisa Gersh, Mezerville Roberto De, Nicholas Sheridan Lewin, Raj Denhoy and Renee Gaeta.
View institutional ownership trends.

Shares of ESTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.